The Role of Trastuzumab (Herceptin) in the Treatment of Women with HER2/neu-overexpressing Metastatic Breast Cancer
Research Question(s)
In women with HER2/neu-overexpressing breast cancer:
- Compared with adjuvant or neoadjuvant chemotherapy alone, does trastuzumab in combination with chemotherapy improve clinically meaningful outcomes (overall response rate, time-to-disease-progression, overall survival, toxicity, or quality of life)?
- Compared with placebo or observation, does single-agent trastuzumab adjuvant or neoadjuvant therapy improve clinically meaningful outcomes?
- What is the best way to identify women who will benefit from adjuvant or neoadjuvant trastuzumab therapy?
- What are the adverse events associated with adjuvant or neoadjuvant trastuzumab therapy?
- What are the optimal dose, schedule, and duration for adjuvant trastuzumab therapy?
Modality:
Immunotherapy
PEBC:
PEBC
Guideline Identifier:
1-15 Version 3
Cancer Continuum:
Treatment
Cancer Type:
Type of Content:
Authors:
Breast Cancer Disease Site Group
Universal Date:
2011-09-15 00:00:00